While the pharmaceutical side was hitting record highs, the basketball franchise was navigating a "Journey of Pain"—a strategic rebuild aimed at long-term contention.
: This strategic retreat allowed them to pick up Taylor Hendricks at ninth overall in the 2023 draft, a foundational piece for their current roster. 3. Broader 2023 Franchise Trends Jazzy franchise23.jpg
: Net product sales for Xywav increased by 39% in the second quarter alone, reaching blockbuster status. While the pharmaceutical side was hitting record highs,
: The 2022-2023 season started surprisingly well (27-29 by the trade deadline), but management chose to trade key veterans like Mike Conley to secure better draft odds. Broader 2023 Franchise Trends : Net product sales
: The oncology portfolio was on a tear, with Rylaze sales jumping 43% year-over-year by Q3. 2. The Utah Jazz: The "Quiet" Rebuild
2023 was the year of "holding the line" for the sports world and "breaking through" for the pharma world. As we look at the data from Jazz Pharmaceuticals and the NBA standings today, it's clear that the bold moves made in 23 are finally paying off.
: The sector added nearly 15,000 units and created roughly 254,000 jobs , despite economic uncertainty.